@orphanbiotec.com
Orphanbiotec AG is a socially responsible, research-based pharmaceutical enterprise specializing in Rare Diseases.
๐ข
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Orphanbiotec is a socially responsible pharmaceutical enterprise specializing in rare diseases. With the help of partners, they aim to provide affordable healthcare solutions to those in need. Their first project focuses on developing a photodynamic therapy for gastric cancer, which includes a novel early diagnostic tool and screening capabilities.
By utilizing this therapy, Orphanbiotec can directly assist approximately 200,000 patients suffering from gastric cancer in the European Union, the U. S., and Canada. This project also opens up possibilities for the development of therapies for other rare and non-rare diseases.
Orphanbiotec was founded in 2009 by Dr. Frank Grossmann and partners, and their management team consists of Dr. Grossmann as CEO, Prof.
Dr. Frank Bau as a strategic advisor, Dr. Doris Hinger as the project manager for development and research, and Daniel des Roches as CFO.
They bring a trusted network of professionals in the medical, pharmaceutical, and economic fields for consultation, research, and teaching
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere ๐
All services online
Top brand categories